CoChat

Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death

Open access
Nick, Alpa M., Stone, Rebecca L., Armaiz-Pena, Guillermo, Ozpolat, Bulent, Tekedereli, Ibrahim, Graybill, Whitney S., Landen, Charles N., Villares, Gabriel, Vivas-Mejia, Pablo, Bottsford-Miller, Justin, Kim, Hye Sun, Lee, Ju-Seog, Kim, Soo Mi, Baggerly, Keith A., Ram, Prahlad T., Deavers, Michael T., Coleman, Robert L., Lopez-Berestein, Gabriel, Sood, Anil K. · 2011 · JNCI: Journal of the National Cancer Institute
Cited by 51

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: We investigated the clinical and biological significance of p130cas, an important cell signaling molecule, in ovarian carcinoma. METHODS: Expression of p130cas in ovarian tumors, as assessed by immunohistochemistry, was associated with tumor characteristics and patient survival. The effects of p130cas gene silencing with small interfering RNAs incorporated into neutral nanoliposomes (siRNA-DOPC), alone and in combination with docetaxel, on in vivo tumor growth and on tumor cell proliferation (proliferating cell nuclear antigen) and apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling) were examined in mice bearing orthotopic taxane-sensitive (HeyA8 and SKOV3ip1) or taxane-resistant (HeyA8-MDR) ovarian tumors (n = 10 per group). To determine the specific mechanisms by which p130cas gene silencing abrogates tumor growth, we measured cell viability (MTT assay), apoptosis (fluorescence-activated cell sorting), autophagy (immunoblotting, fluorescence, and transmission electron microscopy), and cell signaling (immunoblotting) in vitro. All statistical tests were two-sided. RESULTS: Of 91 ovarian cancer specimens, 70 (76%) had high p130cas expression; and 21 (24%) had low p130cas expression. High p130cas expression was associated with advanced tumor stage (P < .001) and higher residual disease (>1 cm) following primary cytoreduction surgery (P = .007) and inversely associated with overall survival and progression-free survival (median overall survival: high p130cas expression vs low expression, 2.14 vs 9.1 years, difference = 6.96 years, 95% confidence interval = 1.69 to 9.48 years, P < .001; median progression-free survival: high p130cas expression vs low expression, 1.04 vs 2.13 years, difference = 1.09 years, 95% confidence interval = 0.47 to 2.60 years, P = .01). In mice bearing orthotopically implanted HeyA8 or SKOV3ip1 ovarian tumors, treatment with p130cas siRNA-DOPC in combination with docetaxel chemotherapy resulted in the greatest reduction in tumor growth compared with control siRNA therapy (92%-95% reduction in tumor growth; P < .001 for all). Compared with control siRNA therapy, p130cas siRNA-DOPC reduced SKOV3ip1 cell proliferation (31% reduction, P < .001) and increased apoptosis (143% increase, P < .001) in vivo. Increased tumor cell apoptosis may have persisted despite pan-caspase inhibition by the induction of autophagy and related signaling pathways. CONCLUSIONS: Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djr372

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 51

Metadata

Authors
Nick, A. M., Stone, R. L., Armaiz-Pena, G., Ozpolat, B., Tekedereli, I., Graybill, W. S., Landen, C. N., Villares, G., Vivas-Mejia, P., Bottsford-Miller, J., Kim, H. S., Lee, J.-S., Kim, S. M., Baggerly, K. A., Ram, P. T., Deavers, M. T., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K.
Venue
JNCI: Journal of the National Cancer Institute
Published
2011-09-28
Volume
103
Issue
21
Pages
1596-1612
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2136989259
Cited by
51
References
2
FWCI
7.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. https://app.cochat.ai/papers/10.1093/jnci/djr372
The paper
Nick, A. M., Stone, R. L., Armaiz-Pena, G., Ozpolat, B., Tekedereli, I., Graybill, W. S., Landen, C. N., Villares, G., Vivas-Mejia, P., Bottsford-Miller, J., Kim, H. S., Lee, J.-S., Kim, S. M., Baggerly, K. A., Ram, P. T., Deavers, M. T., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011). Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djr372

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.